X0508 4 2024-01-03 false 0001560241 G1 Therapeutics, Inc. GTHX 0001806147 Bailey John E. (Jack) Jr. 700 PARK OFFICES DRIVE, SUITE 200 RESEARCH TRIANGLE PARK NC 27709 true true false false President and CEO false Common Stock 2024-01-03 4 A false 100700.00 0.00 A 501280.00 D Common Stock 2024-01-03 4 S false 2592.00 3.1189 D 498688.00 D Common Stock 2024-01-03 4 S false 9094.00 3.1189 D 489594.00 D Stock Options (Right to Buy) 2.97 2024-01-03 4 A false 201300.00 0.00 A 2034-01-03 Common Stock 201300.00 201300.00 D Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Each RSU represents a contingent right to receive one share of Issuer common stock. Represents (i) 131,130 shares of common stock; (ii) 28,750 RSUs from award granted on January 3, 2022; (iii) 80,700 RSUs from award granted on January 3, 2023; (iv) 160,000 RSUs from award granted on May 10, 2023; and (v) 100,700 RSUs from award granted on January 3, 2024. The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person. The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents (i) 134,288 shares of common stock; (ii) 23,000 RSUs from award granted on January 3, 2022; (iii) 80,700 RSUs from award granted on January 3, 2023; (iv) 160,000 RSUs from award granted on May 10, 2023; and (v) 100,700 RSUs from award granted on January 3, 2024. Represents (i) 145,369 shares of common stock; (ii) 23,000 RSUs from award granted on January 3, 2022; (iii) 60,525 RSUs from award granted on January 3, 2023; (iv) 160,000 RSUs from award granted on May 10, 2023; and (v) 100,700 RSUs from award granted on January 3, 2024. The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Note: On January 3, 2024 the reporting person was also granted performance-based restricted stock units that are subject to material conditions beyond the reporting person's control, and, therefore, not considered derivative securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and excluded from this report. /s / Monica Roberts Thomas, attorney-in-fact 2024-01-05